AZD5055 for Idiopathic Pulmonary Fibrosis

"This clinical trial seeks 90 participants with usual interstitial pneumonia, aged between 18 and 55. Eligible applicants must fulfill the following criteria: healthy males/females of non-childbearing age (Part 1 - 18 to 55 years old; Part 2 - Males from18 to55, Females from 18 to 49), have a body mass index within the range of 18 and 30 kg/m2, weigh no less than 50kgs, female subjects must take a negative pregnancy test prior joining in addition male subjects & their partners should use reliable contraception methods throughout the study period plus an additional 17 days after taking part."

"Affirmative. According to clinicaltrials.gov, this experiment is actively seeking volunteers after being posted on November 18th 2021 and last updated December 1st 2022. Aspiring participants will need to come from one site, with the trial needing 90 enrollees in total."

"This clinical trial will evaluate the number of participants with adverse effects over a 53-day period. Secondary outcomes include data points such as cumulative amount of unchanged drug excreted into urine, area under plasma concentration time curve from zero to infinity and apparent volume of distribution following extravascular administration based on terminal phase."

"Evaluators from Power have assigned AZD5055 a score of 1 based on the limited data available for its safety and efficacy profile, as this is only in Phase 1 trials."

"Affirmative. The information hosted on clinicaltrials.gov reveals that this investigation is actively recruiting participants, having been first posted on November 18th 2021 and most recently amended on December 1st 2022. In total, 90 individuals are required for enrolment at a single medical site."

"Eligible participants for this trial must have an age between 18 to 55. For individuals below or above those ages, there are 7 and 91 studies respectively that may accommodate their needs."